Clinical trialNCT07069699RecruitingPhase 1/PHASE2Interventional

Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene

SponsorNational Cancer Institute (NCI)Enrollment50Burkitt LymphomaDouble-Expressor LymphomaHigh Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase Ib/II trial tests the safety, side effects, best dose and how well giving CX-5461 works for the treatment of patients with B-cell non-Hodgkin lymphoma. CX-5461 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving CX-5461 may be safe, tolerable and/or effective in treating patients with B-cell non-Hodgkin lymphoma.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Sami Ibrahimi
Yale University Cancer Center LAO
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Uci Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California, United States
Nicole Foley
Recruiting
Uc Irvine Health/chao Family Comprehensive Cancer Center
Orange, California, United States
Nicole Foley
Recruiting
University of Kansas Clinical Research Center
Fairway, Kansas, United States
Aung M. Tun
Recruiting
University of Kansas Cancer Center
Kansas City, Kansas, United States
Aung M. Tun
Recruiting
University of Kansas Hospital-Indian Creek Campus
Overland Park, Kansas, United States
Aung M. Tun
Recruiting
University of Kansas Hospital-Westwood Cancer Center
Westwood, Kansas, United States
Aung M. Tun
Recruiting
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
Sami Ibrahimi
Recruiting
Upmc Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
Jing-Zhou Hou
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Pidnarulex

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 13 Oct 2026
Primary completion: 31 Jan 2030
Completion: 31 Jan 2030
Last update posted: 31 Jul 2026
Registered enrollment: 50
Registry id: NCT07069699

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.